Analysis of The Domestic Tetracycline And Chloramphenicol Market in The 17th Week of 2022
Florfenicol is actively exploring prices, manufacturers are reluctant to sell it, and the market price is 430-445. At present, the price has bottomed out and rebounded. The psychological expectation of market purchases is high, and the delivery of upstream terminals is tight. The price in the same period last year was around 580.
Doxycycline hydrochloride, the decline tightened, the market price was around 430, down 36% within half a year. When the product reaches a certain height, it will slowly decline. This is a market law, and we must treat it rationally; Asia Pacific and the Data Analysis Center will pay close attention to it.
Oxytetracycline and oxytetracycline hydrochloride continue to be weak, with continuous closures and controls in various places, and market transactions are not smooth. The price of oxytetracycline in the past three years has remained in the range of 83-86, and the price of oxytetracycline hydrochloride is low, and the quotation is 102-103
Chlortetracycline hydrochloride, driven by rising market sentiment, has better demand and the market price is around 210; manufacturers of chlortetracycline hydrochloride: Fujian Fukang, Pucheng Chia Tai, Jinhe Biological
Looking for chemical products? Let suppliers reach out to you!
2026-06-30
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Market Analysis of Domestic Veterinary Drug Raw Materials in the 34th Week of 2022
-
Market Analysis of Tetracycline and Chloramphenicol in Week 16
-
Market Analysis of Tetracycline and Chloramphenicol in Week 16
-
Market Analysis of Tetracycline and Chloramphenicol Raw Materials
-
Market Analysis of Tetracycline and Chloramphenicol Raw Materials
-
Market Analysis of Tetracycline And Chloramphenicol
-
Market Analysis of Tetracycline And Chloramphenicol
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
Recommend Reading
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
Indian CRDMOs See Growth as Global Pharma Diversifies Operations
-
US Senator Investigates GSK's Removal of Asthma Inhaler Amid Crisis
-
New Medicines Restore Heart Function in 25 Percent of Heart Failure Patients
-
Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
-
Melamine: Toxicity, Industrial Resin Uses, and Food Safety Scandals
-
Palm Oil Market Strengthens in March
-
Permanganate: Properties, Uses, and Safety
-
This Week, the TDI Market in China Continues to Decline (9.1-9.5)
-
DMF Market Primarily Operates Strongly